About BioMarin Pharmaceutical
BioMarin Pharmaceutical is a company based in San Rafael (United States) founded in 1997. BioMarin Pharmaceutical has raised $37.5 million across 7 funding rounds from investors including Pfizer, Temasek and BB Biotech Ventures. The company has 3,040 employees as of December 31, 2024. BioMarin Pharmaceutical has completed 7 acquisitions, including Amicus Therapeutics, Inozyme Pharma and Kuvan. BioMarin Pharmaceutical operates in a competitive market with competitors including Ultragenyx, Alnylam, Gemini Therapeutics, Mirum Pharmaceuticals and Immusoft, among others.
- Headquarter San Rafael, United States
- Employees 3040 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biomarin Pharmaceutical Inc.
-
Annual Revenue
$2.84 B (USD)17.35as on Dec 31, 2024
-
Net Profit
$426.86 M (USD)154.62as on Dec 31, 2024
-
EBITDA
$626.23 M (USD)109.56as on Dec 31, 2024
-
Total Equity Funding
$37.5 M (USD)
in 7 rounds
-
Latest Funding Round
$500 M (USD), Post-IPO
May 11, 2020
-
Investors
Pfizer
& 3 more
-
Employee Count
3040
as on Dec 31, 2024
-
Investments & Acquisitions
Amicus Therapeutics
& 6 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BioMarin Pharmaceutical
BioMarin Pharmaceutical is a publicly listed company on the NASDAQ with ticker symbol BMRN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of BioMarin Pharmaceutical
Unlock access to complete
Unlock access to complete
Software Development Team
179 people
Leadership Team
154 people
Senior Team
62 people
Operations Team
52 people
Product Management Team
39 people
Legal and Compliance
33 people
Finance and Accounting
25 people
Sales and Marketing
20 people
Unlock access to complete
Funding Insights of BioMarin Pharmaceutical
BioMarin Pharmaceutical has successfully raised a total of $37.5M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $500 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BioMarin Pharmaceutical
BioMarin Pharmaceutical has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Temasek and BB Biotech Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
An investment platform is provided for diverse sectors and geographies.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
ROMA99 is recognized as a trusted online gaming platform.
|
Locked | Locked | Locked |
Investor details for BioMarin Pharmaceutical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioMarin Pharmaceutical
BioMarin Pharmaceutical has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include Amicus Therapeutics, Inozyme Pharma and Kuvan.
Investment portfolio details for BioMarin Pharmaceutical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of treatments for rare and debilitating metabolic diseases
|
Locked | Locked | 2016 | Locked | |
|
Drug discovery company developing therapeutics for cancer and infectious diseases treatment.
|
Locked | Locked | 2006 | Locked | |
|
Small molecule therapeutics targeting glycan biosynthesis are developed.
|
Locked | Locked | 2004 | Locked |
Complete acquisition details for BioMarin Pharmaceutical
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - BioMarin Pharmaceutical
Detailed financials for BioMarin Pharmaceutical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biomarin Pharmaceutical Comparisons
Peer comparison for BioMarin Pharmaceutical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BioMarin Pharmaceutical
BioMarin Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ultragenyx, Alnylam, Gemini Therapeutics, Mirum Pharmaceuticals and Immusoft, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
B cells are programmed as biofactories for therapeutic protein delivery.
|
Detailed competitors of BioMarin Pharmaceutical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biomarin Pharmaceutical
Complete news archive for BioMarin Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioMarin Pharmaceutical
BioMarin Pharmaceutical was founded in 1997.
BioMarin Pharmaceutical is headquartered in San Rafael, United States. It is registered at San Rafael, California, United States.
Jean Jacques Bienaime is the current CEO of BioMarin Pharmaceutical.
BioMarin Pharmaceutical is a funded company, having raised a total of $37.5M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at BioMarin Pharmaceutical is 3,040.
Annual revenue of BioMarin Pharmaceutical is $2.84B as on Dec 31, 2024.
BioMarin Pharmaceutical was founded in 1997 and is headquartered in San Rafael, United States. Therapeutics are developed by the company for rare genetic diseases within the biopharmaceutical sector. Multiple products have been created for conditions including mucopolysaccharidosis syndrome and phenylketonuria. Additional therapies are being advanced for disorders such as Duchenne muscular dystrophy, hemophilia A, and Pompe disease. Operations focus on research and product development for these specialized treatments.
BioMarin Pharmaceutical's top competitors include Alnylam, Pharvaris and Ultragenyx.
Yes, BioMarin Pharmaceutical is publicly traded on NASDAQ under the ticker symbol BMRN.
BioMarin Pharmaceutical has made 7 acquisitions, including Amicus Therapeutics, Inozyme Pharma, and Kuvan.
The ticker symbol of BioMarin Pharmaceutical is BMRN on NASDAQ.